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Abstract
During early vertebrate development, members of the transforming growth factor beta (TGF) family play important roles in a variety
of processes, including germ layer specification, patterning, cell differentiation, migration, and organogenesis. The activities of TGFs need
to be tightly controlled to ensure their function at the right time and place. Despite identification of multiple regulators of Bone
Morphogenetic Protein (BMP) subfamily ligands, modulators of the activin/nodal class of TGF ligands are limited, and include follistatin,
Cerberus, and Lefty. Recently, a membrane protein, tomoregulin-1 (TMEFF1, originally named X7365), was isolated and found to contain
two follistatin modules in addition to an Epidermal Growth Factor (EGF) domain, suggesting that TMEFF1 may participate in regulation
of TGF function. Here, we show that, unlike follistatin and follistatin-related gene (FLRG), TMEFF1 inhibits nodal but not activin in
Xenopus. Interestingly, both the follistatin modules and the EGF motif contribute to nodal inhibition. A soluble protein containing the
follistatin and the EGF domains, however, is not sufficient for nodal inhibition; the location of TMEFF1 at the membrane is essential for
its function. These results suggest that TMEFF1 inhibits nodal through a novel mechanism. TMEFF1 also blocks mesodermal, but not
epidermal induction by BMP2. Unlike nodal inhibition, regulation of BMP activities by TMEFF1 requires the latter’s cytoplasmic tail, while
deletion of either the follistatin modules or the EGF motif does not interfere with the BMP inhibitory function of TMEFF1. These results
imply that TMEFF1 may employ different mechanisms in the regulation of nodal and BMP signals. In Xenopus, TMEFF1 is expressed from
midgastrula stages onward and is enriched in neural tissue derivatives. This expression pattern suggests that TMEFF1 may modulate nodal
and BMP activities during neural patterning. In summary, our data demonstrate that tomoregulin-1 is a novel regulator of nodal and BMP
signaling during early vertebrate embryogenesis.
© 2003 Elsevier Science (USA). All rights reserved.
Introduction
TGF signaling has been implicated in multiple pro-
cesses during early vertebrate development. Two main
classes of TGF ligands play different roles in patterning of
the early embryos (for reviews, see Hogan, 1996; Harland
and Gerhart, 1997; Schier and Shen, 1999; Whitman, 2001).
The activin/nodal subfamily participates in specification of
endoderm and mesoderm in pregastrula embryos. At gas-
trula stages, ligands in this group are involved in dorsal
mesoderm formation as well as anterior–posterior pattern-
ing. Later in development, these factors are part of the
regulatory network that determines left–right asymmetry of
the vertebrate body axis and functions to influence the
dorsal–ventral patterning of the nervous system. Members
of a second class of TGF ligands, the Bone Morphogenetic
Proteins (BMPs), are involved mainly in ventralization of
all germ layers in the early embryo, resulting in suppression
of neural and dorsal mesodermal cell fates. Subsequently,
BMPs participate in formation and patterning of multiple
tissues and organs, including the neural crest, heart, blood,
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kidney, limb, muscle, and skeletal elements. The diverse
activities of both groups of TGF ligands are mediated by
closely related homologues in conserved signal transduction
pathways, but they are also subject to differential regulation
by other factors (Massague, 1998; Massague and Chen,
2000).
TGF signals are transduced inside cells through two
types of membrane serine–threonine kinase receptors. Upon
binding to ligands, type II receptors phosphorylate type I
receptors (activin receptor-like kinases, or ALKs), which
then activate cytoplasmic signal transducers, called Smads.
Activated Smads are translocated from the cytoplasm to the
nucleus and cooperate with other transcription factors to
influence gene expression (for reviews, see Derynck and
Feng, 1997; Massague, 1998; Massague and Chen, 2000).
Though the pathway is conserved for most TGF members,
nodal signal transduction does require an additional com-
ponent, the cripto/criptic/FRL1/one-eyed-pinhead protein
(Schier and Shen, 1999; Shen and Schier, 2000; Whitman,
2001). The cripto family proteins contain a divergent EGF
domain and a conserved CFC motif, and they function as
coreceptors for nodal. In the absence of cripto, the type I
receptor ALK4 can mediate signal transduction from ac-
tivin, but not from nodal (Gritsman et al., 1999). Through
direct binding to both ALK4 and nodal, cripto allows inter-
action of nodal with ALK4 to stimulate downstream re-
sponses (Reissman et al., 2001; Yeo and Whitman, 2001).
Cripto is therefore a unique component in the TGF path-
way, which may be required specifically for nodal-related
ligands.
TGF signals can be regulated by factors at different
cellular levels. For example, the naturally occurring trun-
cated receptor BAMBI inhibits signaling by both classes of
TGF ligands at the membrane (Onichtchouk et al., 1999);
and the inhibitory Smads, Smad6 and Smad7, block trans-
duction of TGF signals in the cytoplasm (Nakao et al.,
1997; Casellas and Hemmati-Brivanlou, 1998; Hata et al.,
1998; Nakayama et al., 1998). The predominant regulation
of TGF signals, however, occurs at the extracellular level.
Many secreted factors have been found to antagonize the
activities of TGF ligands in early embryos, and they in-
clude noggin, chordin, follistatin, Cerberus, Gremlin, Xnr3,
and lefty (Smith and Harland, 1992; Hemmati-Brivanlou et
al., 1994; Sasai et al., 1995; Piccolo et al., 1996, 1999;
Zimmerman et al., 1996; Hansen et al., 1997; Hsu et al.,
1998; Branford et al., 2000; Cheng et al., 2000; Tane-
gashima et al., 2000). Interestingly, though all of these
proteins can inhibit the function of BMPs, only a subset of
these modulates activin/nodal activity. Cerberus blocks
nodal, but not activin signaling through direct binding to
nodal (Piccolo et al., 1999); and lefty has been proposed to
prevent interaction of activin/nodal with their receptors by
occupying these receptors (Sakuma et al., 2002). Follistatin,
the first identified secreted factor to regulate signals from
the activin/nodal group of ligands, inhibits activin but not
Vg1 through specific, high affinity binding to activin
(Kogawa et al., 1991; Fukui et al., 1993). The regulation of
nodal signaling by follistatin has not been demonstrated.
While these three regulators of activin/nodal signals do not
share sequence homology, several other proteins with fol-
listatin domains have been recently identified. Follistatin
contains three repetitive cystein-rich motifs, called follista-
tin (FS) modules. Proteins containing FS modules have
been identified in a variety of species. These proteins con-
tain either a single FS module, as seen in the follistatin-
related proteins (FRPs; Mashimo et al., 1997; Okabayashi et
al., 1999; De Groot et al., 2000) and follistatin-like (Flik;
Patel et al., 1996; Towers et al., 1999), or they have two or
more FS modules, such as in follistatin-related gene (FLRG,
which has two FS modules, Hayette et al., 1998; or FSRP,
Schneyer et al., 2001). Like follistatin, FLRG binds to
activin with high affinity and blocks activin signaling
(Schneyer et al., 2001; Tsuchida et al., 2001; Bartholin et
al., 2002). These data suggest that proteins with FS modules
may participate in regulation of activin/nodal activities.
Recently, a transmembrane protein with two FS modules
was isolated from several species (Eib and Martens, 1996;
Uchida et al., 1999; Eib et al., 2000; Da Silva et al., 2001).
This protein, tomoregulin-1 (TMEFF1, previously named
7365), also contains an EGF motif in its extracellular re-
gion. The function of TMEFF1 in the regulation of TGF
signals has not been demonstrated. In this study, we report
that, unlike follistatin, TMEFF1 selectively inhibits nodal,
but not activin in Xenopus ectodermal explants. Both the FS
and the EGF domains contribute to the nodal inhibitory
function of TMEFF1. A soluble protein containing the FS
modules and the EGF motif, however, is not sufficient for
nodal inhibition; membrane localization of the protein is
also required. Furthermore, we show that TMEFF1 also
inhibits mesodermal, but not epidermal induction by BMP2.
Interestingly, the regulation of BMPs requires the cytoplas-
mic tail of TMEFF1; the follistatin modules are dispensable
for this activity if the EGF motif is present, and vice versa.
These results imply that different strategies may be em-
ployed by TMEFF1 to inhibit nodal and BMPs. Our data
thus suggest that TMEFF1 regulates nodal and BMP sig-
naling through novel mechanisms.
Materials and methods
Construction of TMEFF1 mutants
All mutants were constructed by using PCR-based clon-
ing strategies. For TMEFF1-C, PCR was done with
TMEFF-N: GGGAATTCACCATGGATGGATTGCAC-
CCT and C-C: GGCTCGAGCTAAATACACATGA-
CAATTGC. The PCR fragment was digested with EcoRI
and XhoI and inserted into the pCS2 vector. For
TMEFF1-TC, PCR was performed with TMEFF-N and
TC-C: GCTCTAGACTAGGTGAGCTTTTGCCTACT;
the PCR product was digested with EcoRI and XbaI and
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inserted into the pCS2 vector. For TMEFF1-FS, PCR
was done with EGF-N: CGCCACAATGGCATAGAAAC-
AGATGAAACA and TMEFF-C: GGGTCTAGACTACA-
CCATCCGGGAAGAAGT. The PCR product was cut with
BglI and XbaI and ligated into the BglI/XbaI-digested
pCS2TMEFF1. For TMEFF1-EGF, PCR was per-
formed with TM-N: GAAGGCCTTTATGTGGTTCCAA-
GTAGG and TMEFF-C. The PCR product was double
digested with StuI and XbaI, and ligated into the StuI/XbaI-
digested pSC2TMEFF1. For XFS-TMEFF1, PCR was
done with follistatin template with XFS-N: GCGGAATT-
CACCATGTTAAATGAAAGGATC and XFS-C: GCGA-
AGCTTCTTACAGTTGCAAGATCCACT. The PCR pro-
duct was digested with EcoRI and HindIII. PCR was
also performed with TMEFF1 template with TMEFF-
EGFN: GCGAAGCTTATAGAAACAGATGAAACAA-
GC and TMEFF-C. The PCR product was digested with
HindIII and XbaI. The two digested PCR products were
ligated and inserted into the EcoRI/XbaI sites of the
pCS2vector.
RT-PCR
For TMEFF1 temporal expression, the following two
primers were used for RT-PCR assay: TMEFF1-U, CGAC-
CCGAGGTGAAAGAT; and TMEFF1-D, GTTTTGCT-
TCTGCCGTCG. Primers used for other markers are as
described (Chang et al., 1997).
Whole-mount in situ hybridization
In situ hybridization was performed as described (Har-
land, 1991). The TMEFF1 probe was synthesized with T7
polymerase, using NotI linearized pBSKS-TMEFF1 tem-
plate.
Results
Selective inhibition of nodal and BMP2, but not activin,
by TMEFF1
TMEFF1 is a transmembrane protein of about 370 amino
acids. It has been isolated from Xenopus, newt, mouse, and
human (Eib and Martens, 1996; De Groot et al., 2000; Eib
et al., 2000; Da Silva et al., 2001). It contains two follistatin
modules and an EGF motif in its extracellular domain. Since
follistatin and FLRG can inhibit activin activities, and
TMEFF1 contains two FS modules, we tested whether
TMEFF1 could also inhibit activin. RNAs encoding
TMEFF1 and activin were coinjected into the animal pole of
two-cell-stage embryos. The ectodermal explants (animal
caps) of injected embryos were dissected at blastula stages,
and gene expression in these explants was analyzed at
gastrula stages by RT-PCR. As shown in Fig. 1A, TMEFF1
does not block activin activity (lanes 3 and 4). Both meso-
dermal markers, such as Brachyury (Xbra; Smith et al.,
1991) and Chordin (Sasai et al., 1994), and endodermal
markers, such as Sox17 (Hudson et al., 1997), are induced
by activin in the presence of TMEFF1. To test the speci-
ficity of TMEFF1 for other members of the TGF family,
we challenged the activity of nodal, Vg1, and BMP2. Chi-
meric nodal and Vg1 proteins, AXnr1 (Piccolo et al., 1999)
and AVg1 (Kessler and Melton, 1995), containing the ac-
tivin pro-domain conjugated to Xnr1 and Vg1 mature pep-
tides, respectively, were used to ensure maximum secretion
of these ligands. TMEFF1 strongly inhibits AXnr1 (Fig. 1A,
lanes 5 and 6), and also blocks AVg1 and BMP2 (Fig. 1A,
lanes 7–10). To examine the inhibitory efficiency of
TMEFF1 toward AXnr1, AVg1, and BMP2, we performed
a dose-response experiment. A fixed amount (0.5 ng) of the
three TGF ligand RNAs was coinjected with increasing
doses of TMEFF1 RNA (0.5, 1, and 2ng) at the two-cell
stage. Marker expression in animal caps from injected em-
bryos was then analyzed at gastrula stages. As shown in Fig.
Fig. 1. TMEFF1 inhibits nodal and BMP2, but not activin, activity. (A)
TMEFF1 does not inhibit mesendoderm induction by activin, but it does
block nodal and reduces Vg1 and BMP2 activity. The doses of RNAs used
are: activin, 5 pg; AXnr1, 0.5 ng; AVg1, 0.5 ng; BMP2, 0.5 ng; and
TMEFF1, 2 ng. (B) Dose-response experiment demonstrating that
TMEFF1 inhibits nodal and BMP2 efficiently, but has a weaker inhibitory
activity toward Vg1. The doses of RNA used are: AXnr1, 0.5 ng; AVg1,
0.5 ng; BMP2, 0.5 ng; and TMEFF1, 0.5, 1, and 2 ng, respectively.
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1B, TMEFF1 inhibits AXnr1 efficiently; the lowest dose of
TMEFF1 is able to abolish gene induction by this ligand
(Fig. 1B, compare lanes 3–5 with lane 2). TMEFF1 also
effectively blocks mesodermal induction by BMP2 (Fig.
1B, compare lanes 11–13 with 10), but it displays a lower
efficiency in suppressing AVg1 (Fig. 1B, compare lanes 7–9
with 6). These results suggest that TMEFF1 can regulate a
subset of TGF ligands; however, TMEFF1 differs from
follistatin in that it does not inhibit activin.
Since nodal-related ligands, but not activin, can be in-
hibited by the soluble antagonist Cerberus (Piccolo et al.,
1999), we examined the possibility that TMEFF1 might
block nodal function through induction of Cerberus in ec-
todermal explants. RT-PCR analysis demonstrates that Cer-
berus is not expressed in animal caps, and its expression is
not activated by TMEFF1 (not shown). The data thus indi-
cate that TMEFF1 may not regulate nodal signaling through
this secreted nodal antagonist, though it may cooperate with
Cerberus.
To further compare the ligand specificity for proteins
containing FS-modules (Fig. 2A), we coexpressed follistatin
(XFS), TMEFF1, and the follistatin-related gene (FLRG)
with the TGF ligands activin, AXnr1, and AVg1 in early
Xenopus embryos. Animal caps from injected embryos
were removed at blastula stages, and gene expression pat-
terns were analyzed at gastrula (Fig. 2B) or tailbud (Fig. 2C)
stages by RT-PCR. As shown in Fig. 2, these three FS-
motif-containing proteins display different specificities to-
ward TGF ligands. FLRG is a specific antagonist of activin
and does not interfere with mesoderm induction by AXnr1
and AVg1 (Fig. 2B and C, compare lanes 8, 12, and 16 with
lanes 5, 9, and 13, respectively). While follistatin inhibits
activin completely, it modifies mesoderm induction by
AXnr1 and AVg1, changing the character of the mesoderm
toward more dorsal fates. At gastrula stages, ventral meso-
dermal markers induced by AXnr1 and AVg1, such as
Xwnt8 and Xhox3, are suppressed by follistatin; dorsal
mesodermal and endodermal markers, such as chordin and
mixer, are enhanced (Fig. 2B, compare lanes 11 and 15 with
lanes 9 and 13, respectively). At tailbud stages, the axial
mesodermal marker, type II collagen, which is expressed in
the notochord, is induced by these ligands in the presence of
follistatin, while the paraxial muscle marker, muscle actin,
is inhibited (Fig. 2C, compare lanes 11 and 15 with lanes 9
and 13, respectively). Follistatin also induces neural tissues,
as the expression of the neural marker NRP-1 is stimulated
in the caps at tailbud stages (Fig. 2C). Dorsalization of
mesoderm and neural induction by follistatin likely reflect
the ability of follistatin to block BMP activities in addition
to activin (Iemura et al., 1998). Consistent with the results
shown in Fig. 1, TMEFF1 does not inhibit activin, but it
does suppress gene activation by AXnr1 and AVg1 (Fig. 2B
and C). Our data indicate that three proteins with follistatin
modules have differential function in the regulation of
TGF signaling.
Interestingly, though TMEFF1 inhibits mesoderm induc-
tion by BMP2 (Fig. 1), it does not induce neural markers in
animal caps (Fig. 2C). TMEFF1, however, does induce
markers for cement gland, a structure outside of the anterior
neural tissue whose formation requires partial inhibition of
BMPs (Wilson et al., 1997; data not shown). This result
suggests that TMEFF1 may be a weak inhibitor of the
epidermal-inducing activity of the BMPs. To test this hy-
pothesis, we performed a cell dissociation assay. RNAs
encoding BMP2 and different doses of TMEFF1 were in-
jected into animal poles of two-cell-stage embryos. At blas-
tula stages, the animal caps were removed from injected
embryos and dissociated in calcium- and magnesium-free
Fig. 2. Differential regulation of TGF ligands by follistatin-module-
containing molecules. (A) Schematic representation of the three FS mod-
ule-containing proteins. SS, signal sequence; FS, follistatin modules; EGF,
EGF domain; TM, transmembrane region. (B, C) Follistatin (XFS), FLRG,
and TMEFF1 display differential inhibitory spectrums over TGF ligands.
While both XFS and FLRG inhibit activin, TMEFF1 does not affect
mesoderm induction by activin. TMEFF1, however, blocks nodal and Vg1
function. The doses of RNAs used are: TMEFF1, 1 ng; follistatin (XFS),
1 ng; human FLRG, 1 ng; activin, 5 pg; AXnr1, 500 pg; AVg1, 500 pg;
BMP2, 500 pg. The RNAs were injected into the animal region of two-
cell-stage embryos, and the animal caps were dissected at blastula stages
(stage 9). The caps were collected at gastrula stages (stage 11, B) or tailbud
stages (stage 28, C) for RT-PCR assays of gene expression patterns.
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buffer for 4 h. The cells were then aggregated and incubated
to early tailbud stages for RT-PCR analysis of epidermal
and neural markers. As reported before (Wilson et al.,
1997), prolonged cell dissociation followed by reaggrega-
tion changes cell fate from epidermal to neural, so that
epidermal keratin expression is down-regulated and the ex-
pression of the neural marker NRP-1 is activated (Fig. 3
compare lane 2 with lane 1). BMP2 restores the epidermal
fate and inhibits neural formation in dissociated caps (Fig.
3, lane 3). Increasing doses of TMEFF1, while sufficient to
block mesoderm induction by BMP2 (Fig. 1B), cannot re-
verse epidermal induction by BMP2 (Fig. 3, compare lanes
4–6 with lane 3). The data suggest that TMEFF1 differen-
tially regulates the mesodermal- and epidermal-inducing
activities of the BMPs (see Discussion).
Membrane localization of TMEFF1 is required for its
nodal-inhibiting activity
Both follistatin and FLRG inhibit activin by directly
binding to the ligand, preventing interaction with the activin
receptors (Kogawa et al., 1991; Fukui et al., 1993; Tsuchida
et al., 2001; Bartholin et al., 2002). The follistatin modules
in these proteins are likely to play an important role in
ligand binding. We therefore tested whether the follistatin
modules in tomoregulin-1 were sufficient for nodal inhibi-
tion. A mutant TMEFF1 that contains only the two follista-
tin motifs (TMEFF1-FS; Fig. 4A) was made and coex-
pressed with AXnr1 in early Xenopus embryos.
TMEFF1-FS is not able to block AXnr1 activity in animal
caps: all markers induced by AXnr1 are still expressed in
the presence of this mutant (Fig. 4B, compare lane 8 with
lane 6). The data suggest that additional sequences are
required for the nodal inhibitory function of TMEFF1. To
see whether the extracellular domain, which contains both
the follistatin and EGF motifs, is sufficient for nodal inhi-
bition, we constructed a mutant protein with a C-terminal
deletion that eliminates the transmembrane region and the
cytoplasmic tail (TMEFF1-TC; Fig. 4A). This mutant,
TMEFF1-TC, can be secreted from oocytes injected with
its RNA, suggesting that it is a secreted protein (Fig. 4C).
Coexpression of TMEFF1-TC with AXnr1 in ectodermal
explants shows that, like TMEFF1-FS, TMEFF1-TC does
not block gene activation by AXnr1 (Fig. 4B, lane 9). This
result demonstrates that secreted TMEFF1 does not inhibit
nodal function and that TMEFF1 may need to be located at
the membrane to function as a nodal inhibitor.
TMEFF1 from all species contains a conserved cytoplas-
mic tail, which may be important for nodal inhibition (Eib
and Martens, 1996; Uchida et al., 1999; Eib et al., 2000; Da
Silva et al., 2001). To see whether the cytoplasmic region is
required for TMEFF1 function, we constructed a mutant
TMEFF1 that has deletion in the cytoplasmic domain right
after the transmembrane region (TMEFF1-C; Fig. 4A).
Unlike TMEFF1-TC, injection of TMEFF1-C into oo-
cytes does not generate detectable protein from conditioned
medium (Fig. 4C), suggesting that the transmembrane re-
gion is sufficient to retain the protein in cells. Coexpression
of TMEFF1-C with AXnr1 shows that this mutant pos-
sesses nodal inhibitory activity (Fig. 4B, lane 10). Our data
therefore demonstrate that, unlike the soluble proteins fol-
listatin and FLRG, the membrane localization of TMEFF1
is essential for its function.
Both the FS modules and the EGF motif contribute to
nodal inhibition
Since soluble TMEFF1 is not sufficient for nodal inhi-
bition and membrane localization is required for TMEFF1
function, it is possible that TMEFF1 interacts with mem-
brane proteins that are involved in nodal signal transduc-
tion. This interaction may require only the follistatin mod-
ules or the EGF motif; alternatively, both domains may be
required. To examine whether the follistatin modules and
the EGF domain are required for tomoregulin-1 activity, we
constructed two additional mutant proteins that have either
the EGF or the FS domains removed, respectively
(TMEFF1-EGF and TMEFF1-FS; Fig. 5A). As shown in
Fig. 5B, deletion of either the FS modules or the EGF motif
reduces the ability of TMEFF1 to block nodal function
(compare lanes 4 and 5 with lane 3). The data show that, in
addition to the follistatin modules, the EGF motif also
contributes to the nodal-inhibiting activity of TMEFF1. Our
data thus suggest that TMEFF1 inhibits nodal through a
novel mechanism.
Inhibition of nodal activity by a follistatin–TMEFF1
chimeric protein
The follistatin modules have been proposed to mediate
the TGF-regulatory activities of FS module-containing
proteins. The differential regulation of activin and nodal by
follistatin and TMEFF1 may therefore depend on sequence
Fig. 3. TMEFF1 does not block epidermal induction by BMP2. Animal
caps from control or injected embryos were dissociated at blastula stages
(stage 9) for 4 h before reaggregation and incubation to tailbud stages
(stage 22), at which time the RNA was extracted for RT-PCR analysis of
marker expression. RNAs used for injection are: BMP2, 0.5 ng; and
TMEFF1, 0.5 1, and 2 ng, respectively.
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differences in their follistatin motifs. To examine this pos-
sibility, we constructed a chimeric XFS-TMEFF1 protein,
in which the FS modules of TMEFF1 are replaced with the
FS modules of follistatin (Fig. 6A). We coexpressed XFS-
TMEFF1 with either activin or AXnr1 in early Xenopus
embryos and analyzed gene expression induced by these
ligands in the presence of the chimeric protein. Interest-
ingly, as shown in Fig. 6B, XFS-TMEFF1 not only retains
the nodal inhibitory activity of TMEFF1, but it also acquires
the activin inhibitory function of follistatin. This result
suggests that the FS modules in TMEFF1 may not be
critical in the determination of ligand specificity. The data
again imply that TMEFF1 regulates nodal function through
a novel membrane-dependent mechanism.
Regulation of BMP activity by TMEFF1 requires its
cytoplasmic tail
Since TMEFF1 not only inhibits nodal, but also blocks
mesoderm induction by BMP2 (Fig. 1), we wanted to ex-
amine whether inhibition of BMP2 by TMEFF1 also re-
quires the membrane location and both the FS and the EGF
Fig. 4. Membrane localization of TMEFF1 is required for its nodal-inhibiting function. (A) Schematic representation of the deletion mutants used in this study.
SS, signal sequence; FS, follistatin modules; EGF, EGF domain; TM, transmembrane region. (B) Membrane location of TMEFF1 is important for nodal
inhibition. Neither the mutant protein containing the FS modules alone nor the secreted protein containing the entire extracellular domain of TMEFF1 is
sufficient to block nodal function. Deletion of the cytoplasmic tail, however, does not abolish the inhibitory activity of TMEFF1. RNA (2 ng) was injected
for TMEFF1 and all mutants, and 500 pg of AXnr1 was used. (C) The mutant containing the extracellular domain only (TC), but not the mutant with the
cytoplasmic tail deletion and intact transmembrane region (C), is secreted into the medium from injected oocytes. RNA (40 ng) was used for all TMEFF1
constructs in oocyte injections. The injected oocytes were incubated in the presence of 35S-methionine-labeling mix, and the conditioned supernatants were
collected 2 days after injection and run on SDS-PAGE.
Fig. 5. Both the FS modules and the EGF motif contribute to nodal
inhibition. (A) Schematic representation of the mutant proteins used. (B)
Deletion of either the follistatin modules or the EGF domain reduces the
ability of TMEFF1 to block nodal. The doses of RNA used in this exper-
iment: AXnr1, 500 pg; and TMEFF1 and all deletion mutants, 2 ng.
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domains. We therefore coexpressed BMP2 with different
deletion mutants of TMEFF1 and assayed for marker ex-
pression in animal caps from injected embryos at gastrula
stages. Interestingly, neither the soluble TMEFF1 (TC)
nor the membrane protein with the extracellular domain and
transmembrane region of TMEFF1 (C) inhibits BMP2
efficiently (Fig. 7, compare lanes 4 and 5 with lane 3). This
result implies that, unlike regulation of nodal, inhibition of
BMP2 requires the cytoplasmic tail of TMEFF1. In addi-
tion, deletion of either the follistatin modules (FS) or the
EGF motif (EGF) does not impair the BMP inhibitory
function of TMEFF1 (Fig. 7, compare lanes 7 and 8 with
lane 3). Our results suggest that TMEFF1 may use different
mechanisms to block nodal and BMP signals, and inhibition
of BMP by TMEFF1 may involve intracellular signaling
downstream of TMEFF1.
Overexpression of TMEFF1 in early Xenopus embryos
induces anterior defects
Nodal signaling is required for endoderm and mesoderm
formation in early frog embryos; interference with this sig-
naling pathway hinders mesendoderm development and can
lead to anterior truncation of frog tadpoles (Osada and
Wright, 1999; Agius et al., 2000). BMPs are involved in
ventral patterning of early frog embryos (Harland and Ger-
hart, 1997). If TMEFF1 regulates signals from these TGF
ligands, then overexpression of TMEFF1 should interfere
with early frog development. To examine this possibility,
we injected different doses (0.5, 1, and 2 ng) of TMEFF1
RNA into either two dorsal or two ventral blastomeres of
four-cell-stage embryos. As shown in Fig. 8, while ventral
expression of TMEFF1 causes tail truncation, overexpres-
sion of TMEFF1 on the dorsal side induces anterior defects
in frog embryos, leading to the reduction or even absence of
head structures. The cement gland and eyes are gradually
lost in injected embryos. At higher doses, some embryos
also show a failure in blastopore closure (not shown). Con-
trol injection of RNA encoding CD2, a membrane protein,
does not lead to any embryonic defects (not shown). The
morphology of the tadpoles injected with TMEFF1 RNA
resembles that induced by expression of the dominant-neg-
ative nodal ligand cmXnr2 (Osada and Wright, 1999), im-
plying that, like cmXnr2, TMEFF1 may also inhibit nodal
activity in whole frog embryos. The phenotype induced by
cmXnr2, however, may not be due to a complete inhibition
of nodal signaling in vivo, as it has been shown that cmXnr2
still retains some of its signaling capacity, possibly through
alternative processing (Eimor and Harland, 2002). In addi-
tion, cmXnr2 may also block BMP activities through het-
erodimerization with BMP ligands (Yeo and Whitman,
2001; Eimor and Harland, 2002). The similarity of the
phenotypes between TMEFF1 and cmXnr2 embryos there-
fore suggests that, like cmXnr2, TMEFF1 may induce an-
terior defects through partial inhibition of both nodal and
BMP activities.
Expression of TMEFF1 during early Xenopus development
TMEFF1 was originally identified as a gene expressed in
the hypothalamo–hypophysial axis of the adult Xenopus
brain (Eib and Martens, 1996). The expression of the gene
Fig. 7. Inhibition of mesoderm induction by BMP2 requires the cytoplasmic
domain of TMEFF1. Deletion of the cytoplasmic tail or the transmembrane
region of TMEFF1 reduces the ability of TMEFF1 to inhibit BMP2, while
deletion of either the FS modules or the EGF motif does not impair the BMP
inhibitory activity of TMEFF1. The doses of RNA used in this experiment are:
BMP2, 0.5 ng; and TMEFF1 and the deletion mutants of TMEFF1, 1 ng.
Fig. 6. The FS modules in TMEFF1 do not determine ligand specificity.
(A) Schematic representation of the chimeric protein constructed. In XFS-
TMEFF1, the FS modules of TMEFF1 are replaced with the FS modules
of XFS. (B) The chimeric protein XFS-TMEFF1 inhibits both activin and
nodal activities. The doses of RNA used are: activin, 5 pg; AXnr1, 500 pg;
TMEFF1, 2 ng; XFS, 2 ng; and XFS-TMEFF1, 2 ng.
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at early developmental stages in frogs has not been reported.
To see when and where TMEFF1 is expressed during early
frog embryogenesis, we analyzed its temporal expression
profile by reverse transcription PCR (RT-PCR) and its spa-
tial distribution by whole-mount in situ hybridization. As
shown in Fig. 9A, TMEFF1 is first transcribed at midgas-
trula stages (stage 10.5). The expression level increases
during neurula stages and remains at least to tadpole stages
(Fig. 9A). At gastrula stages, TMEFF1 is expressed mainly
in ectodermal tissues and weakly in the marginal zone, but
is absent from the vegetal region (Fig. 9B). During early
neurulation, TMEFF1 transcripts are detected in the neural
plate (Fig. 9C, a). As neurulation proceeds, TMEFF1 RNA
is restricted to the neural folds and the dorsal neural tube in
the trunk region (Fig. 9C, b–d). At tailbud stages, TMEFF1
is expressed in the diencephalon, midbrain, hindbrain (Fig.
9c, f), otic vesicle, and the cranial nerve placodes (Fig. 9C,
e and f) in addition to trunk dorsal neural tissue. This
temporal and spatial expression pattern suggests that
TMEFF1 may not participate in the early function of nodal,
during germ layer formation, but may regulate TGF sig-
naling during neural development.
Discussion
During early vertebrate development, TGF signals reg-
ulate many aspects of embryonic induction and patterning.
The activities of TGFs are under the control of both
positive and negative factors (Hill, 2001). Follistatin, a
negative regulator of both activin and BMPs, contains three
repetitive modules that may be important for its inhibitory
function. Proteins harboring different numbers of follistatin
modules have been recently identified. FLRG, which has
two FS motifs, acts similarly to follistatin in that it binds to
activin with high affinity and blocks activin signaling. The
activities of Flik/FRPs, which contain single FS modules, in
the regulation of TGF signals, however, have not been
documented in detail. Here, we show that TMEFF1, a pro-
tein with two FS modules, regulates nodal and BMP, but not
activin activities. This is the first example in which proteins
with follistatin motifs have been shown to regulate nodal
function. Our data, however, demonstrate that, though re-
quired, FS modules in TMEFF1 are not sufficient for nodal
inhibition: both a second structural motif, the EGF domain,
and expression of the protein at the membrane, are addi-
tionally necessary for nodal inhibition. Our results thus
suggest that TMEFF1 regulates nodal activities through a
novel mechanism.
How does TMEFF1 selectively block nodal but not ac-
tivin signaling? In general, there are several potential mech-
anisms. First, TMEFF1 may bind specifically to nodal, but
not activin to prevent activation of the downstream recep-
tors, leading to selective inhibition of nodal activity. This
strategy of discriminatory interaction with a subset of li-
gands is utilized widely for regulation of TGF members,
by factors such as follistatin and other BMP antagonists
(e.g., Zimmerman et al., 1996; Iemura et al., 1998). In the
case of TMEFF1, however, a mutant protein (TMEFF1-
TC) that lacks the transmembrane domain and is secreted
is not sufficient for nodal inhibition. The membrane local-
ization is required for the anti-nodal effects of TMEFF1.
This suggests that, if TMEFF1 does bind to nodal selec-
tively, extracellular binding by itself is not sufficient to
prevent nodal signaling. Selective binding of nodal by
TMEFF1 at the cell membrane is required. A second pos-
sible mechanism is that TMEFF1 may stimulate the expres-
sion and/or activity of nodal antagonists, such as Cerberus
(Piccolo et al., 1999) or Lefty (Cheng et al., 2000; Tane-
gashima et al., 2000), which in turn block nodal signaling.
In Xenopus, Lefty inhibits both activin- and nodal-related
Fig. 8. Ectopic expression of TMEFF1 interferes with anterior development of early Xenopus embryos. TMEFF1 RNA (0.5–2 ng) was injected into two dorsal
or two ventral blastomeres of four-cell-stage embryos; and the injected embryos were analyzed at tailbud stages for morphological changes. While ventral
expression of TMEFF1 leads to tail defects, dorsal expression of TMEFF1 results in reduction of anterior structures.
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ligands (Cheng et al., 2000; Tanegashima et al., 2000),
indicating that it cannot be responsible for selective inhibi-
tion of nodal by TMEFF1. Cerberus specifically blocks
nodal but not activin in frogs (Piccolo et al., 1999), but the
gene is not expressed in animal caps at gastrula stages.
Overexpression of TMEFF1 does not activate Cerberus
transcription. The data thus suggest that TMEFF1 does not
inhibit nodal through up-regulation of the known nodal
antagonists. Currently, we cannot rule out the possibility
that TMEFF1 stimulates some as yet unidentified nodal
antagonist. A third potential mechanism is that TMEFF1
may block nodal activity through interaction with signaling
components that are unique to the nodal pathway. Activin
and nodal signals are mediated by many common factors,
including the type I and the type II receptors, the cytoplas-
mic Smad signal transducers, and the nuclear transcription
factors, such as FAST (FoxHI; for reviews, see Schier and
Shen, 1999; Whitman, 2001). Nodal, but not activin, how-
ever, also requires a family of cripto/criptic/one-eyed pin-
head (oep) proteins as a coreceptor for its binding to the
type I receptor ALK4 for subsequent signaling (Shen and
Schier, 2000; Reissmann et al., 2001; Yeo and Whitman,
2001). Cripto family members contain a divergent EGF
domain and a novel CFC motif, and the CFC domain inter-
acts directly with ALK4 to mediate nodal signal activation
(Yeo and Whitman, 2001). Since TMEFF1 inhibits nodal
only when it is located on the plasma membrane, it is
possible that TMEFF1 interacts with Cripto proteins to
prevent functional ligand–receptor complex formation in
the presence of nodal. This mechanism would allow
TMEFF1 to distinguish between nodal and activin. A fourth
possible mechanism is that TMEFF1 activates a down-
stream signal or serves as a ligand to activate other signaling
pathways; and the crosstalk between the TMEFF1-depen-
dent signal and the TGF pathway leads to inhibition of
nodal. Since secreted TMEFF1 loses its activity, it is un-
likely that TMEFF1 functions as a ligand to stimulate a
nodal inhibitory signal. In addition, the mutant that lacks the
Fig. 9. Temporal and spatial expression of TMEFF1 during early Xenopus development. (A) TMEFF1 is expressed from midgastrula stages onward. (B) At
gastrula stages (stage 11–11.5), TMEFF1 is expressed mainly in ectodermal tissues (animal), weakly in the marginal zone (DMZ and VMZ, dorsal and ventral
marginal zone, respectively), and is absent from the vegetal region. (C) Spatial expression of TMEFF1. (a) TMEFF1 is expressed in the neural plate at early
neurula stages. The embryo is viewed from the dorsal side. (b–d) As neurulation proceeds, TMEFF1 expression is enriched in the neural folds and in the
dorsal neural tube (b and d, dorsal view; c, lateral view). (e, f) At tailbud stages, TMEFF1 is detected in the diencephalon, midbrain, hindbrain, otic vesicles,
cranial nerve placodes, and the trunk dorsal neural tissue. di, diencephalon; mb, midbrain; hb, hindbrain; nt(d), neural tube (dorsal); ot, otic vesicle; pl, cranial
nerve placodes. The embryo is viewed laterally ( e) and dorsolaterally (f).
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cytoplasmic tail can still inhibit nodal, suggesting that sig-
naling through TMEFF1 may not be required either. Further
investigation is needed to distinguish between these possi-
ble mechanisms of TMEFF1 action.
In addition to nodal inhibition, TMEFF1 also blocks
mesodermal induction by BMP2. TMEFF1 seems to
achieve BMP inhibition through a distinct mechanism. A
mutant that lacks the cytoplasmic domain of TMEFF1,
which still retains its nodal inhibitory function, loses its
ability to block BMP2. Furthermore, while deletion of either
the follistatin modules or the EGF motif reduces the ability
of TMEFF1 to block nodal, these deletions do not seem to
affect the effectiveness of BMP inhibition. The results sug-
gest that TMEFF1 may activate an intracellular pathway to
inhibit BMP function. Interestingly, we observe that, though
TMEFF1 blocks mesodermal induction by BMP2 effi-
ciently, it does not block epidermal induction by BMP2
well, and it does not induce neural markers in animal caps.
This phenomenon may be explained by several mecha-
nisms. Much higher doses of BMP are required for meso-
derm induction than for epidermal induction, and the dif-
ferences of TMEFF1 in inhibition of the two inductive
processes may be due to the efficiency of BMP inhibition by
TMEFF1. Alternatively, the TMEFF1-activated intracellu-
lar pathway may selectively interfere with mesodermal but
not epidermal patterning by BMPs. If this is the case, then
the TMEFF1-dependent mechanism may work at a step
downstream of the cytoplasmic signal transducer Smad1, as
Smad1 is shared by both mesodermal and epidermal induc-
tion processes. Further investigations are required to under-
stand the mechanism of BMP inhibition by TMEFF1.
In Xenopus, TMEFF1 RNA is not expressed in early
embryos. The transcripts can be detected by RT-PCR only
at gastrula stages. This temporal expression pattern differs
from that seen in the mouse. During mouse development,
TMEFF1 (m7365) is expressed in preimplantation embryos,
and expression is maintained following implantation in both
embryonic and extraembryonic tissues (De Groot et al.,
2000). The difference in expression patterns of TMEFF1
therefore suggests that, unlike in mice, where TMEFF1 may
regulate early nodal activity, TMEFF1 in frogs may not be
involved in nodal regulation during germ layer formation
and patterning. Other TMEFF homologues, including
TMEFF2 (tomoregulin; Horie et al., 2000; Kanemoto et al.,
2001), may exist in frogs, and they may be expressed during
early frog embryogenesis to regulate nodal function in mes-
endoderm formation. Later in development, expression of
TMEFF1 in both frogs and mice is enriched in neural tissues
(de Groot et al., 2000; Eib et al., 2000), suggesting that
TMEFF1 may participate in modulation of nodal and BMP
activities during neural patterning and differentiation.
In summary, we demonstrate in our studies that tomo-
regulin-1 (TMEFF1) can selectively inhibit nodal and BMP
function. The membrane location of TMEFF1 is important
for its nodal inhibitory activity, while the cytoplasmic re-
gion is required for BMP inhibition by TMEFF1. Our data
suggest that tomoregulin-1 may regulate nodal and BMP
signaling through novel mechanisms.
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